Humira can cause side effects that range from mild to serious. Examples include injection site reactions, rash, and infections. The active ingredient in Humira is adalimumab. The drug comes as an ...

“That means because you inject a really small amount, you can vaccinate more people with a limited supply” Schaffner adds. “And that’s the intention here.” This technique isn’t new, he adds.

AbbVie introduced a high-potency, low-volume formulation of Humira (adalimumab) without citrate buffers - which can cause pain at the injection site - in 2018, that has grown rapidly since then ...

But until then AbbVie has been making the most of Humira’s dominant position in the US inflammatory disease market, with sales increasing nearly 7% in Q1 to more than $3.9 billion.

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.